{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:28:23Z","timestamp":1790270903915,"version":"4.1.0"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,17]]},"DOI":"10.7759\/cureus.8660","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T11:37:50Z","timestamp":1592393870000},"source":"Crossref","is-referenced-by-count":6,"title":["Ceftriaxone-Induced Immune Hemolytic Anemia"],"prefix":"10.7759","author":[{"given":"Anil","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Singhania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhankar","family":"Samal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1900554","article-title":"Warm autoimmune hemolytic anemia","volume":"381","author":"Brodsky RA","year":"2019","unstructured":"Brodsky RA. Warm autoimmune hemolytic anemia. N Engl J Med. 2019, 381:647-654. 10.1056\/NEJMcp1900554","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01173.x","article-title":"One center\u2019s experience: the serology and drugs associated with drug-induced immune hemolytic anemia? A new paradigm","volume":"47","author":"Johnson ST","year":"2007","unstructured":"Johnson ST, Fueger JT, Gottschall JL. One center\u2019s experience: the serology and drugs associated with drug-induced immune hemolytic anemia? A new paradigm. Transfusion. 2007, 47:697-702. 10.1111\/j.1537-2995.2007.01173.x","journal-title":"Transfusion"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13187","article-title":"Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review","volume":"102","author":"Tanios GE","year":"2019","unstructured":"Tanios GE, Doley PB, Munker R. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. Eur J Haematol. 2019, 102:157-162. 10.1111\/ejh.13187","journal-title":"Eur J Haematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.04.004","article-title":"The changing spectrum of drug-induced immune hemolytic anemia","volume":"42","author":"Arndt PA","year":"2005","unstructured":"Arndt PA, Garratty G. The changing spectrum of drug-induced immune hemolytic anemia. Semin Hematol. 2005, 42:137-144. 10.1053\/j.seminhematol.2005.04.004","journal-title":"Semin Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03321.x","article-title":"Serologic characteristics of ceftriaxone antibodies in 25 patients with drug-induced immune hemolytic anemia","volume":"52","author":"Arndt PA","year":"2012","unstructured":"Arndt PA, Leger RM, Garratty G. Serologic characteristics of ceftriaxone antibodies in 25 patients with drug-induced immune hemolytic anemia. Transfusion. 2012, 52:602-612. 10.1111\/j.1537-2995.2011.03321.x","journal-title":"Transfusion"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000440673","article-title":"Variability of findings in drug-induced immune haemolytic anaemia: experience over 20 years in a single centre","volume":"42","author":"Mayer B","year":"2015","unstructured":"Mayer B, Bartolm\u00e4s T, Y\u00fcrek S, Salama A. Variability of findings in drug-induced immune haemolytic anaemia: experience over 20 years in a single centre. Transfus Med Hemotherapy. 2015, 42:333-339. 10.1159\/000440673","journal-title":"Transfus Med Hemotherapy"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/33062-ceftriaxone-induced-immune-hemolytic-anemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:23:05Z","timestamp":1707506585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/33062-ceftriaxone-induced-immune-hemolytic-anemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.8660","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,17]]}}}